Julius Ecuru | Uganda National Council for Science and Technology | 2011 A presentation made at the workshop titled Post-trial access to trial drugs: Legal, ethical and practical issues held at the Brocher Foundation, Geneva on 15 – 16… Continue reading
Mariëtte van Huijstee, Irene Schipper (Editors) | Published by Centre for Research on Multinational Corporations, Salud y Fármacos, Centre for Studies in Ethics and Rights | February 2011 An exploratory study on outsourcing of clinical trials by pharmaceutical companies to… Continue reading
Kowalski C. J. | PubMed | 2010 Spring;53(2):161-73 It is widely accepted that if one is to follow the ethical tenets of clinical equipoise, phase III controlled clinical trials must be designed pragmatically, to measure effectiveness rather than efficacy. This choice… Continue reading
Adriana Petryna | Princeton University Press | 2009 The phenomenal growth of global pharmaceutical sales and the quest for innovation are driving an unprecedented search for human test subjects, particularly in middle- and low-income countries. Our hope for medical progress… Continue reading
Doris Shroeder | RECIIS – Elec. J. Commun. Inf. Innov. Health. Rio de Janeiro, v.2, Sup. 1, p.Sup.63-Sup.73, Dec., 2008 In its essence, post-trial obligations describe a duty by research sponsors to provide a successfully tested drug to research participants… Continue reading
Patralekha Chatterjee | Bulletin of the World Health Organisation | Volume 86, Number 8 | August 2008 According to the Associated Chambers of Commerce and Industry, an influential national industry association, India is set to grab clinical trials business valued… Continue reading
